arrow
P

Paul Fitzpatrick

biomarin pharmaceutical inc.
H指数:35
被引数:4,102

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition
2024-05-170
OAAI
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital
2022-05-014
OAAI
Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type B
2020-01-1510
OAAI
Histologic characterization of the progression of central nervous system pathology in the mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo syndrome type B) mouse model and bio-distribution and efficacy of the intracerebroventricular enzyme replacement therapy, BMN 250
2016-02-011
PREAI
Time- and dose -dependentnormalization of pathological lysosomal storage and biochemistry in the mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo syndrome type B) mouse model by intracerebroventricular enzyme replacement therapy with BMN 250, a NAGLU-IGF2 fusion pro
2016-02-010
PREAI